Fig. 2: Immune response before and after SARS-CoV-2 infection in a GRAd-COV2 vaccinated volunteer.
From: Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
a Timeline detailing the SARS-CoV-2 infection case in terms of vaccination, in-study and out-of-study visits, symptoms onset and swabs outcome until resolution. b IgG binding to S1-S2 measured by CLIA in arm 3 (high dose vaccine in younger age volunteers), with IgG kinetics in the COVID-19 case depicted in red and all remaining volunteers in gray for context. Below each study visit indicated on x axis, the outcome of a qualitative CMIA detecting anti-nucleocapsid (N) IgG is reported for the COVID-19 case. c SARS-CoV-2 neutralizing activity time course in serum from the COVID-19 case, detected by MNA. d T cell response to Spike in arm 3 detected by IFNγ ELISpot on freshly isolated PBMC 2 weeks after vaccination, with the COVID-19 case depicted in red and all remaining volunteers in gray for context. The horizontal line is set at median. e Spike and N T-cell response time course in the COVID-19 case, detected by IFNγ ELISpot on frozen PBMC. DMSO, the peptide pools diluent, represents the assay negative control. The arrow in panels b, c and e highlight timing of SARS-CoV-2 infection. Postinfection visits data in panels c and e are depicted in red.
